XML 21 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 28, 2019
Jun. 29, 2018
Statement of Cash Flows [Abstract]    
Net income $ 154,817 $ 203,351
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 3,998 1,176
Stock-based compensation 27,608 18,588
401(k) matching contributions made in common stock 3,551 2,723
Amortization and other changes in right-of-use assets (7,071) 0
Deferred income taxes 33,067 0
Gain on other equity investments (730) (209)
Accretion of investments, net and other (2,919) (490)
Changes in operating assets and liabilities:    
Trade receivables, net 65,230 (76,698)
Other receivables 3,661 (9,271)
Inventory, net (2,514) (1,714)
Current portion of unbilled collaboration revenue (2,150) 0
Prepaid expenses and other current assets 2,170 (1,577)
Other long-term assets (4,789) 3
Accounts payable 23 (1,535)
Accrued compensation and benefits (7,998) 465
Accrued clinical trial liabilities 5,478 (3,048)
Rebates and fees due customers 2,319 3,578
Accrued collaboration liability 428 (1,261)
Current and long-term deferred revenue 4,656 5,910
Long-term portion of lease liabilities 6,777 (181)
Other current and long-term liabilities 7,709 6,463
Net cash provided by operating activities 293,321 146,273
Cash flows from investing activities:    
Purchases of property and equipment (3,516) (15,182)
Purchases of investments (518,268) (227,012)
Proceeds from maturities of investments 258,791 139,948
Proceeds from sale of investments 11,677 10,237
Proceeds from other equity investments 730 209
Net cash used in investing activities (250,586) (91,800)
Cash flows from financing activities:    
Proceeds from exercise of stock options 10,590 6,550
Proceeds from employee stock purchase plan 4,145 3,650
Taxes paid related to net share settlement of equity awards (2,434) (2,976)
Principal payments on financing lease obligation (22) 0
Net cash provided by financing activities 12,279 7,224
Net increase in cash, cash equivalents and restricted cash 55,014 61,697
Cash, cash equivalents and restricted cash at beginning of period 315,875 188,314
Cash, cash equivalents and restricted cash at end of period 370,889 250,011
Supplemental cash flow disclosure:    
Right-of-use assets obtained in exchange for lease obligations [1] 11,338 17,180
Unpaid liabilities incurred to acquire Property and equipment $ 1,350 $ 13,972
[1]
Amounts for the six months ended June 30, 2019 include receipt of a tenant inventive payment and an amendment to our existing lease for office and research space. Amounts for the six months ended June 30, 2018 include the transition adjustment for the adoption of Topic 842.